Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for BioRestorative Therapies (BRTX) over the last 14 years, with Q3 2025 value amounting to $3.9 million.

  • BioRestorative Therapies' Cash & Equivalents rose 16099.56% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 16099.56%. This contributed to the annual value of $10.2 million for FY2024, which is 105162.44% up from last year.
  • BioRestorative Therapies' Cash & Equivalents amounted to $3.9 million in Q3 2025, which was up 16099.56% from $5.8 million recorded in Q2 2025.
  • BioRestorative Therapies' Cash & Equivalents' 5-year high stood at $17.9 million during Q2 2022, with a 5-year trough of $884377.0 in Q4 2023.
  • In the last 5 years, BioRestorative Therapies' Cash & Equivalents had a median value of $5.8 million in 2025 and averaged $7.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 5222027.2% in 2021, then plummeted by 9194.83% in 2025.
  • Quarter analysis of 5 years shows BioRestorative Therapies' Cash & Equivalents stood at $1.1 million in 2021, then skyrocketed by 51.7% to $1.7 million in 2022, then plummeted by 48.4% to $884377.0 in 2023, then skyrocketed by 1051.62% to $10.2 million in 2024, then tumbled by 61.83% to $3.9 million in 2025.
  • Its Cash & Equivalents stands at $3.9 million for Q3 2025, versus $5.8 million for Q2 2025 and $1.2 million for Q1 2025.